(redirected from Adalat cc)
Also found in: Dictionary, Medical.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for nifedipine

calcium blocker (trade name Procardia)

References in periodicals archive ?
Additionally, incremental 2002 product sales revenues versus 2001 have been favorably impacted by the launch of a bioequivalent version of Adalat CC 90mg and strong sales via the Company's Canadian sales and marketing organization.
Through this distribution arrangement, Elan was able to supply the first generic copy of Adalat CC 30 mg to the US market.
Among ANDAs approved were doxazosin mesylate, the generic equivalent of Cardura for benign prostatic hyperplasia; paclitaxel, the equivalent of the cancer drug Taxol; and nifedipine, the equivalent of Adalat CC for hypertension.
The Adalat Agreement allowed Biovail to introduce into the marketplace Elan's 30mg generic version of Adalat CC earlier than otherwise possible, and subsequently Biovail's own 60mg generic version of Adalat.
dosages are AB rated and bioequivalent to Bayer AG's antihypertensive Adalat CC.
generic version of Adalat CC marketed by Biovail and Teva infringes U.
a Canadianbased company, has been given approval for generic Adalat CC (once-daily nifedipine).
announced today it has filed with the Food and Drug Administration (FDA) Abbreviated New Drug Applications (ANDA) for its generic controlled-release versions of Adalat CC 90mg, Procardia XL 90mg and Tegretol 400mg.
Officials at Bayer, which markets Adalat CC (a CCB for mild to moderate hypertension), also question the methodology used by the researchers.
has called a halt to its pharmacy information program in which it paid pharmacists $35 for each patient they counseled concerning Adalat CC, Miles' drug for patients with high blood pressure.
Eugene Melnyk, Chairman of the Board, commented, "Biovail's 70% increase in total revenues is primarily due to the launch of several new products including generic versions of Voltaren XR and Adalat CC 30 mg and the first commercial launch of a product utilizing Biovail's flash dose technology.
Biovail Corporation (NYSE:BVF)(TSE:BVF) today announced that its in-licensed 30mg dosage strength of generic Adalat CC (once daily nifedipine) has been granted final approval by the Food and Drug Administration (FDA) for immediate marketing in the United States.
Current annual sales of Adalat CC are estimated at $357 million.
today announced that it has received tentative approval for its 30mg and 60mg generic versions of Adalat CC (nifedipine) from the United States Food and Drug Administration ("FDA").